The model enabled estimations of important kinetic parameters, such as PSA and CTC production, CTC lifespan, and their respective interindividual variabilities.
No relationship was observed between clinico-pathological characteristics of these patients and their respective counts of CTC measured by each technique.
Dissimilarities between CTCs and their respective primary tumor might influence a patient's response to therapies selected only on the basis of the characteristics of the primary tumor [ 60, 61].
For instance, HER2 status may vary between primary tumors and their respective metastasis or circulating tumor cells (CTCs) [ 3, 4], and examples of primary invasive breast cancers containing neoplastic cells with and without HER2 amplification are on record [ 5].
The names of CTCs from each district with respective sub actual sample size in the brackets are as follows: - Kinondoni district were Mwananyamala (91), Sinza (92) and Mwenge (3); Ilala district were Amana (95), Buguruni (44) and Mnazimmoja (28); Rungwe district Tukuyu(149), Masukulu 5) and Mwakaleli (14) and from Kyela district were Kyela(155), Njisi 9) and Ngonga(6).
PFS was significantly longer in CTC-HER2-positive patients than in CTC-HER2-negative patients (p = 0.035), the respective median PFS times [95 % CI] being 7.4 [4.7–13.7] and 4.3 [3.5 5.9] months.
When the inhibitors or neutralizing antibodies were injected into the tumor-bearing mice, in vivo invasion and intravasation (that is, the number of CTCs) were significantly inhibited compared with each respective vehicle control, in both MDA-MB-231 tumors and the patient-derived HT17 and HT39 tumors.
Conversely, in one patient with detectable p95HER2-positive CTCs, truncated HER2 expression was not identified in the respective primary tumor.
CCSCs and CTCs were detected (90% efficiency) and classified in accordance with their respective surface marker expression via completely distinct Raman signals of RANs.
Among a total of 51 CTCs identified in patients with early disease, 19 (37%) were CK/HER2-positive, whereas the respective numbers for patients with metastatic disease were 35 out of 103 cells (34%).
